FDA names reproductive/urologic drug division head
Executive Summary
FDA Division of Reproductive & Urologic Drug Products Acting Director Daniel Shames, MD, is named permanent division head. He has been acting director since October. The division's focus under Shames could be female sexual dysfunction and andropause (1"The Pink Sheet" March 18, p. 18). Shames is a member of FDA's Oncology Coordinating Committee and Shelf-Chemical working group...You may also be interested in...
Female Sexual Dysfunction And Andropause Could Be Advisory Cmte. Topics
A focus of FDA's Reproductive & Urologic Drug Products Division under Acting Director Daniel Shames, MD, could be female sexual dysfunction and andropause
AbbVie/Allergan Merger Edges Closer To FTC Clearance
AstraZeneca will reacquire Allergan's investigational IL-23 inhibitor brazikumab, and Nestle is to buy its GI drug Zenpep, which had nine-month revenue of $208m.
Another Sterilization Plant Closes For Upgrades; FDA Monitoring Situation For Device Shortage
The US agency is engaged with an ethylene oxide (EtO) sterilizer in Illinois that has temporarily closed to determine if there are any potential risks to the medical device supply chain. While the plant shut down about a month ago, regulators have only recently been made aware of the decision, which resulted from a law passed last year by the state legislature.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: